Immunotherapy in pancreatic cancer - Current status and future

Langenbeck's Archives of Surgery

Volumn 384, Issue 4, 1999, Pages 396-404

  Staib, Ludger ^a   Link, Karl Heinz ^a   Beger, Hans Günther ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Cancer vaccines; Immune monitoring; Immunotherapy; Monoclonal antibodies; Pancreatic cancer

Indexed keywords

ALPHA INTERFERON; ANTIGEN GA 733; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODIES CO 17 1 A; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEVER; HUMAN; HYPOTENSION; IMMUNOREGULATION; LEUKOPENIA; PANCREAS CANCER; PRIORITY JOURNAL; TARGET ORGAN; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 0032854406     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050220     Document Type: Article

References (82)

1. Agarwal B, Gendler S, Longenecker BM (1998) The biological role of mucins in cellular and immune regulation: prospects for cancer immunotherapy. Mol Med Today 5:397-403
2. Agarwal B, Reddish MA, Longenecker BM (1996) In vitro induction of MUC1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157:2089-2095
3. Agarwal B. Krantz MJ, Reddish MA, Longenecker BM (1998) Cancer-assocated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43-49
4. AImoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
5. Andersson R, Wang X (1998) Patterns of pancreatic cell death: apoptosis versus oncosis. Pancreas 17:281-288
6. Apostolopoulos V, Osinski C, McKenzie IFC (1998) MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 4:315-320
7. Atzpodien J, Koerfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 355:1509-1512
8. Barnd DL. Lan MS, Metzgar RS, Finn OJ (1989) Specific, MHC-unrestricted recognition of tumor associated mucins by human cytotoxic cells. Proc Natl Acad Sci U S A 86:7159-7167
9. Beger HG, Kunz R, Poch B (1996) What is the adequate resectional procedure in pancreatic cancer? In: Beger H, Büchler M, Schoenberg M (eds) Cancer of the pancreas, 1st edn. Universitätsverlag Ulm GmbH, Ulm, pp 361-365
10. Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L ( 1996) Preoperative interleukin-2 subcutaneous immunotherapy may prolong survival time in advanced colorectal cancer patients. Oncology 53:263-268
11. Bubenik J ( 1996) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther 69:1-14
12. Büchler M, Friess H, Schultheiss K-H, Gebhardt C, Kübel R, Muhrer K-H, Winkelmann M, Wagener T, Klapdor R, Kaul M, Müller G, Schulz G, Beger HG (1991) A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 68:1507-1512
13. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman JA (1993) 145 consecutive pancreaticoduodenectomies without mortality. Ann Surg 217:430-438
14. Capella G, Cronauer-Mitra S, Peinado MA, Perucho M (1991) Frequency and spectrum of mutations at codon 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 93:125-131
15. Celis E, Sette A, Grey HM (1995) Epitope selection and development of peptide based vaccines to treat cancer. Semin Cancer Biol 6:329-336
16. Codington JF, Frim DM (1983) Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor. In: Nowotny A (eds) Biomembranes, 1st edn. Plenum Press, New York, pp 207-258
17. Coley WB (1893) The treatment of malignant tumors by repeated inoculation of erysipels: with a report of ten original cases. Am J Med Sci 105:487-511
18. Ding L, El-Nasir L, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PYS, Taylor-Papadimitriou J, Longenecker MB (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC-1 mucin gene: effect of immunization in the growth of murine mammary adenocarcinoma cells transfected with the human MUC-1 gene. Cancer Immunol Immunother 36:9-17
19. Finn OJ (1992) Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 61-77
20. Finn OJ, Barnd DL, Kerr LA, Miceli CM, Metzgar RS (1989) Specific recognition of tumor target antigens by non-MHC-restricted T-cells. In: Metzgar R S, Mitchell M S (eds) Human tumor antigens and specific tumor therapy, 1st edn. Liss, New York, pp 157-164
21. Fossum B, Olsen AC, Thorsby E, Gaudernack G (1995) CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 40:165-172
22. Frodin JE, Harmenberg U, Biberfeld P, Christensson B, Lafvart AK, Krieger A, Shetye J, Wahren B, Mellstedt H (1988) Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 7:309-321
23. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG (1995) Regionale Chemotherapie beim fortgeschrittenen Pankreaskarzinom. Med Klin 90:501-505
24. Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010
25. Gaudernack G, Gjertsen MK (1997) Mutant ras peptide vaccines. Eur J Cancer 33 [Suppl 8]:289(A)
26. Gedde-Dahl III T, Eriksen JA, Thorsby E, Gaudernack G (1992) T-cell response against products of oncogenes: generation and characterization of human T-cell clones specific for p21 rasderived synthetic peptides. Hum Immunol 33:266-274
27. Gilboa E (1996) Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 23:101-107
28. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl III T, Stokke KT, Solheim BG, Egge TS, Soreide O, Thorsby E, Gaudernack G (1996) Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 65:450-453
29. Goedegebuure P, Douville C, Mak S, Spanjaard RS, Jenner K, Goldberg J, Iyengar V, Eberlein T (1997) Loss of proliferation and TCR-zeta in patients with ovarian cancer. Proc Am Assoc Cancer Res 38:358(A)
30. Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy. Its biological nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47-53
31. Grace PA, Pitt A, Longmire W (1990) Pylorus preserving pancreaticoduodenectomy: an overview. Br J Surg 77:968-974
32. Gudjonsson B (1987) Cancer of the pancreas. 50 years of surgery. Cancer 60:2284-2303
33. Haisma HJ, Brakenhoff RH, v. d. Meulen-Muileman I, Pinedo HM, Boven E (1998) Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human β-glucuronidase. Cancer Immunol Immunother 45:266-272
34. Hanyu F, Suzuki M, Imaizumi T (1993) Whipple operation for pancreatic carcinoma: Japanese experience. In: Beger H G (eds) Standards in pancreatic surgery, 1st edn. Springer, Berlin Heidelberg New York, pp 646-653
35. Herfarth C, Klar E (1996) Pancreatic cancer: indication for resective surgery. In: Beger H, Büchler M, Schoenberg M (eds) Cancer of the pancreas, 1st edn. Universitätsverlag Ulm GmbH, UIm, pp 335-340
36. Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9:657-659
37. Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H (1984) Efficient selection of human growth-inhibiting monoclonal antibodies. J Immunol Methods 73:157-167
38. Herlyn D, Zaloudik J, Li W, Wunner W, Speicher DW, Linnenbach A, Somasundaram R, Staib L (1997) Preclinical and clinical evaluation of baculovirus-derived gastrointestinal carcinoma-associated CO17-1A/GA733 (abstract). Proc Am Assoc Cancer Res 38:399
39. Itzkowitz S, Kjeldsen T, Priera A, Hakomori S, Yang U, Kim YS (1991) Expression of Tn, sialyl Tn, and T antigens in human pancreas. Gastroenterology 100:1691-1700
40. Jentoff N (1990) Why are proteins O-glycosylated? Trends Biochem Sci 15:291-296
41. WAF1 recombinant adenovirus. Pancreas 16:107-113
42. Kudo T, Shinoda M, Suzuki M, Katayose Y, Sakurai N, Saeki H (1998) Effective adoptive immunotherapy by LAK cells retargeted with bacterial superantigen-conjugated antibody in xenografted SCID mice. Proc Am Assoc Cancer Res 39:437A
43. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G (1992) The erbB-3 gene in human pancreatic cancer. J Pathol 168:269-273
44. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45:10-19
45. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 45:1-9
46. Lygidakis NJ, Ziras FA, Kyparidou E, Parissis J, Papadopoulo P, Venetsanou B (1995) Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Hepatogastroenterology 42:1039-1052
47. Lygidakis NJ, Dedemati G, Spenzaris N, Theodoropoulou M (1997) Unresectable pancreatic cancer: is a multi-modality approach a promising therapeuti-cal alternative? Hepatogastroenterology 44:1222-1228
48. MacLean GD, Reddish MA, Bowen-Yacyshyn MB, Poppema S, Longenecker BM (1994) Active specific immunotherapy against adenocarcinomas. Cancer Investigation 12:46-56
49. MacLean GD, Reddish MA. Koganty RR. Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival in metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19:59-68
50. Mitchell MS (1988) Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 80:1445-1450
51. Mitchell MS (1992) Principles of combining biomodulators with cytotoxic agents in vivo. Semin Oncol 19[Suppl 4]:51-56
52. Nagai H, Kuroda A, Marioka Y (1986) Lymphatic and local spread of T1 and T2 pancreas cancer: a study of autopsy material. Ann Surg 204:65-71
53. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiesling R (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
54. Nakao A, Harada A, Nonami T, Kaneko T, Takagi H (1996) Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 12:357-361
55. Nitecki SS, Sarr MG, Colby TV, van Heerden JA (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221:59-66
56. Pecher G, Kulbe H, Van H, Sandig V (1998) Recombinant adenoviral vectors expressing mucin (MUC1)-or CEA-epitopes for the use as cancer vaccines. Proc Am Assoc Cancer Res 39:2505(A)
57. Ragnhammar P, Fagerberg J. Frödin J-E, Wersall P, Hansson L-O, Mellstedt H (1995) Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially antiidiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 40:367-375
58. Reisfeld RA, Gillies SD (1996) Recombinant antibody fusion proteins for cancer immunotherapy. Curr Top Microbiol Immunol 213:27-53
59. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmair H, Hirche H, Pichlmayr R, Buggisch P, Witte J, Group GCA1-1S (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183
60. Romagnani S (1994) Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227-257
61. Rosenberg SA (1988) The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 208:121-135
62. Samuel J. Longenecker BM (1995) Development of active specific immunotherapeutic agents based on cancer-associated mucins. Pharm Biotechnol 6:875-890
63. 1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis. Pancreas 16:468-474
64. Schäfer H, Bruns C, Engert A, Güls F, Zieren U, Raab M (1994) The influence of surgical trauma on natural killer cell function in patients with esophageal and gastric cancer. Eur J Surg Oncol 20:265-266(A)
65. Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Roeder C, Buggisch P, Onur A, Kremer B, Kalthoff H, Jensen EV (1997) Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 94:12622-12626
66. Schmielau J, Kalthoff H, Roeder C, Schmiegel W ( 1996) The role of cytokines in pancreatic cancer, Int J Pancreatology 19:157-163
67. Schoenberg MH, Gansauge F, Kunz R (1997) Pylorus-preserving partial duodenopancreatectomy for ductal pancreatic carcinoma. Chirurg 68:1262-1267
68. Sears H, Herlyn M, Herlyn D, Grotzinger P, Steplewski Z, Koprowski H (1981) Ex vivo perfusion of a tumor-containing colon with monoclonal antibody. J Surg Res 31:145-150
69. Sindelar WF, Maher MM, Herlyn D (1986) Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma 5[Suppl 1]:S125-S132
70. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21:195-200
71. Staib L. Link KH, Büchler M (1991) Steigerung der Zytotoxizität spezifischer monoklonaler Antikörper gegen humane Karzinomzellen durch GMCSF in vitro. Onkologie 14:261-265
72. Staib L, Braumüller H, Link KH, Beger HG (1997) Immune reactivity of regional lymph nodes in human pancreatic cancer is decreased compared to blood cells. Proc Am Assoc Cancer Res 38:121(A)
73. Staib L, Braumüller H, Leeser C, Beger HG, Somasundaram R, Li W, Birebent B, Herlyn D (1998) First report of active specific immunization in colorectal and pancreatic cancer patients with CO17-1A vaccine. Langenbecks Arch Chir Suppl (Forumband 1998), pp 53-58
74. Tempero MA, Pour PM, Uchida E (1986) Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma 5[Suppl 1]:S133-S138
75. Thanhäuser A, Böhle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD, Ulmer AJ (1995) The induction of BCG activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40:103-108
76. Trede M, Schwab M (1996) The extensive, palliative cancer operation. Is it worthwhile? What are its aims? Langenbecks Arch Chir Suppl II (Kongreßbd 1996):86-90
77. Trede M, Schwall G, Saeger H (1990) Survival after pancreaticoduodenectomy. Ann Surg 211:447-458
78. Ungefroren H, Voss M, Jansen M, Roeder C, Henne B, Kremer B, Kalthoff H (1998) Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58:1741-1749
79. Wahab ZA, Metzgar RS (1991) Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. Pancreas 6:307-317
80. Wakahara Y, Nawa A, Okamoto T, Hayakawa A, Kikkawa F, Suganuma N, Wakahara F, Tomoda Y (1997) Combination effect of anti-fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 54:48-54
81. Watanapa P, Williamsson RCN (1992) Surgical palliation for pancreatic cancer: developments during the past two decades. Br J Surg 79:8-20
82. Whiteside TL, Parmiani G (1994) Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39:15-21